Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer clinical trial (NCT06659042). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer clinical trial (NCT06659042). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to standard options I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer clinical trial (NCT06659042). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer clinical trial (NCT06659042). Contact the study team or your healthcare provider for specific answers.

Question 5

What side effects should I expect from the treatments involved in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer clinical trial (NCT06659042). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional tests or procedures I will need to undergo if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer clinical trial (NCT06659042). Contact the study team or your healthcare provider for specific answers.

What this study is about